A Phase 1/2 Study to Assess the Safety and Efficacy of MultiStem Therapy in Subjects With Acute Respiratory Distress Syndrome

Trial Profile

A Phase 1/2 Study to Assess the Safety and Efficacy of MultiStem Therapy in Subjects With Acute Respiratory Distress Syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Allogeneic stem cell therapy Athersys (Primary)
  • Indications Adult respiratory distress syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MUST-ARDS
  • Sponsors Athersys
  • Most Recent Events

    • 31 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Nov 2018.
    • 31 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2017.
    • 15 Jan 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top